Results 81 to 90 of about 47,536 (295)
Association of COPD with adverse outcomes in heart failure patients with preserved ejection fraction
ESC Heart Failure, Volume 12, Issue 2, Page 799-808, April 2025.Abstract We performed a systematic review and meta‐analysis to detect the impact of chronic obstructive pulmonary disease (COPD) on the prognosis of heart failure patients with preserved ejection fraction (HFpEF). We systematically screened eligible literature from three electronic databases, PubMed, EMBASE and Cochrane Library, up to April 2023.
Shuo Xu +3 more
wiley +1 more source
Noninvasive imaging of focal atherosclerotic lesions using fluorescence molecular tomography [PDF]
, 2014 Insights into the etiology of stroke and myocardial infarction suggest that rupture of unstable atherosclerotic plaque is the precipitating event. Clinicians lack tools to detect lesion instability early enough to intervene, and are often left to manage ...
Abendschein, Dana R. +9 more
core +2 more sources
“Rebranding” Natriuretic Peptides [PDF]
Clinical Chemistry, 2020 James L, Januzzi, Nasrien E, Ibrahim
openaire +2 more sources
Biomarkers of lung congestion and injury in acute heart failure
ESC Heart Failure, Volume 12, Issue 2, Page 781-789, April 2025.Abstract Acute heart failure (AHF) classification and management are primarily based on lung congestion and/or hypoperfusion. The quantification of the vascular and tissue lung damage is not standard practice though biomarkers of lung injury may play a relevant role in this context.
Marco Guazzi +9 more
wiley +1 more source
MELD score predicts outcomes in patients with advanced heart failure: A longitudinal evaluation
ESC Heart Failure, Volume 12, Issue 2, Page 839-847, April 2025.Abstract Aims Advanced heart failure (AHF) is characterized by recurrent episodes of haemodynamic instability and frequent hospitalizations, leading to a progressive decline in quality of life and high mortality rates. The objectives of this study were to evaluate the effect of the model for end‐stage liver disease (MELD) score and its variations in ...
Francesco Curcio +10 more
wiley +1 more source
Clinical Use of Natriuretic Peptides
Proceedings of Singapore Healthcare, 2011 Either B-type natriuretic peptide (BNP) or NT-proBNP may be used as a diagnostic, screening, prognostic and therapeutic tool for CHF. The Food and Drug Administration (FDA) cleared the cut-off point for BNP at 100 pg/mL, and that of NT-proBNP at 125 pg ...
Clementine YF Yap MT(ASCP), DLM(ASCP) +2 more
doaj +1 more source
SA Heart Journal, 2017 Serum levels of natriuretic peptides (BNP and NT- proBNP) are known to increase in cardiac failure, and aid in the diagnosis and management of such patients.
J.A. Moolman, L. Du Preez, G. Rossouw
doaj +1 more source
NT -pro BNP as a Mediator of the Racial Difference in Incident Atrial Fibrillation and Heart Failure. [PDF]
, 2019 Background Blacks harbor more cardiovascular risk factors than whites, but experience less atrial fibrillation ( AF ). Conversely, whites may have a lower risk of heart failure ( CHF ).
Alonso, Alvaro +12 more
core
Natriuretic peptide receptors regulate cytoprotective effects in a human ex vivo 3D/bioreactor model [PDF]
, 2013 © 2013 Peake et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and ...
Achan, P +8 more
core +3 more sources
ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya +9 more
wiley +1 more source